Javelin Pharmaceuticals’s stock had lost more than a quarter of its value as of late this morning. This comes on the heels of the Cambridge, MA-based drug developer (AMEX:[[ticker:JAV]]) announcing this morning that its late-stage clinical of intranasal ketamine (Ereska) showed “borderline” statistical improvement over placebo in treating pain after orthopedic surgery. According to Google Finance, the company’s stock was down 54 cents or 26.47 percent to $1.50 per share for the day, as of 11:12 am ET.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
